Sarah Proehl

ORCID: 0009-0008-8255-3560 · 1 paper in corpus

article 2023

Relugolix Combination Therapy in Women With Uterine Fibroids and Adenomyosis: LIBERTY 1 and 2 Trials [ID: 1345355]

·doi:10.1097/01.aog.0000929840.36823.a1

INTRODUCTION: Adenomyosis and uterine fibroids (UFs) may coexist in women with heavy menstrual bleeding (HMB). Relugolix combination therapy (Relugolix-CT: relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) is approved in the Un…